Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 307

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 307
---
       | 680 |
|                            |     |                                | 165 |     |       | 436 |     |                              | 325 |     |       | 954 |

All of the stock option expense for the periods ended December 31, 2023, and 2022, has been recognized as additional paid in capital. The aggregate intrinsic value of stock options outstanding as well as stock options exercisable was nil as of December 31, 2023, and 2022, respectively. As of December 31, 2023, there was $ 603 in unrecognized compensation expense that will be recognized over the next 2.36 years.

The following table sets forth changes in unvested stock options under all plans:

| Unvested at June 30, 2023     |     | Number ofOptions(in thousands) | 118 |   |     | Weightedaverageexerciseprice$ | 24.12 |
|:------------------------------|:----|:-------------------------------|----:|:--|:----|:------------------------------|------:|
| Granted                       |     |                                |  89 |   |     |                               |  4.66 |
| Vested                        |     |                                | (40 | ) |     |                               | 19.68 |
| Forfeited                     |     |                                | (31 | ) |     |                               |  8.26 |
| Unvested at December 31, 2023 |     |                                | 136 |   |     |                               | 16.33 |

The aggregate intrinsic value of unvested stock options at December 31, 2023, was nil (2022 - nil ). The unvested stock options have a remaining weighted average contractual term of 9.00 years (2022 - 9.18 ).

<div align='center'>F-6 3</div>

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

Restricted stock units

During the six months ended December 31, 2023, the Company recognized a total of $ 85 (2022 - nil ) in compensation expense related to RSUs.

| Balance - June 30, 2023              |     | Number ofRSU(in thousands) | 78 |   |
|:-------------------------------------